A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ

Oncotarget

Volumn 6, Issue 11, 2015, Pages 8676-8686

  Tan, Guosheng ^a   Cao, Xinping ^b   Dai, Qiangsheng ^a   Zhang, Bing ^a   Huang, Jianwen ^a   Xiong, Shiqiu ^c   Yu Zhang, Yong ^a   Chen, Wei ^a   Yang, Jianyong ^a   Li, Heping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cell proliferation; miR 129 5p; Survival; TAZ; YAP

Indexed keywords

CISPLATIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN A; MICRORNA; MICRORNA 129 5P; UNCLASSIFIED DRUG; CTGF PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; MESSENGER RNA; MIRN129 MICRORNA, HUMAN; OLIGONUCLEOTIDE; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; RNA; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; WWTR1 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; IN VITRO STUDY; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; TAZ GENE; UPREGULATION; YAP GENE; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; MIDDLE AGED; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN A; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDES; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84928719762     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3254     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. Cancer J Clin. 2009; 59:225-249.
2. Cho KR, Shih Ie M. Ovarian cancer. Ann Rev Pathol. 2009; 4:287-313.
3. Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res. 2002; 107:99-118.
4. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010; 3:11.
5. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009; 40:1213-1223.
6. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010; 2010:932371.
7. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013; 13:246-257.
8. Huang J, Wu S, Barrera J, Matthews K, Pan D. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorkie, the drosophila homolog of YAP. Cell. 2005; 122:421-434.
9. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008; 28:2426-2436.
10. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, Zhao S, Xiong Y, Lei QY, Guan KL. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem. 2010; 285:37159-37169.
11. Oka T, Mazack V, Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem. 2008; 283:27534-27546.
12. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Gene Dev. 2008; 22:1962-1971.
13. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009; 284:13355-13362.
14. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem. 2009; 284:14347-14358.
15. Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011; 71:2728-2738.
16. Shimomura T, Miyamura N, Hata S, Miura R, Hirayama J , Nishina H. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity. Biochem Biophys Res Commun. 2014; 443:917-923.
17. Wang L, Chen Z, Wang Y, Chang D, Su L, Guo Y, Liu C. TR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer. Tumour Biol. 2014; 35:463-468.
18. Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T, Inazawa J. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis. 2011; 32:389-398.
19. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011; 30:2181-2186.
20. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, group AS Bowtell DD, Harvey KF. The hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011; 30:2810-2822.
21. Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010; 70:8517-8525.
22. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, Lim DS. The hippo-salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107:8248-8253.
23. Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, Avruch J. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A. 2011; 108:E1312-1320.
24. Reddy BV, Irvine KD. Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell. 2013; 24:459-471.
25. Fan R, Kim NG, Gumbiner BM. Regulation of hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad Sci U S A. 2013; 110:2569-2574.
26. Piccolo S, Cordenonsi M, Dupont S. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res. 2013; 19:4925-4930.
27. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012; 18:1511-1517.
28. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
29. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
30. Jeong GO, Shin SH, Seo EJ, Kwon YW, Heo SC, Kim KH, Yoon MS, Suh DS, Kim JH. TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. Cell Physiol Biochem. 2013; 32:253-263.
31. Hay BA, Guo M. Coupling cell growth, proliferation, and death. Hippo weighs in. Dev Cell. 2003; 5:361-363.
32. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the salvador/warts pathway. Nat Cell Biol. 2003; 5:914-920.
33. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD, Guan KL. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol. 2012; 14:1322-1329.
34. Zhang Y, Lai ZC. Mob as tumor suppressor is regulated by bantam microRNA through a feedback loop for tissue growth control. Biochem Biophys Res Commun. 2013; 439:438-442.
35. Nolo R, Morrison CM, Tao C, Zhang X, Halder G. The bantam microRNA is a target of the hippo tumor-suppressor pathway. Curr Biol. 2006; 16:1895-1904.
36. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM, Yang PC. MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the hippo pathway and LZTS1. Nat Commun. 2013; 4:1877.
37. Liu AM, Xu Z, Luk JM. An update on targeting hippo-YAP signaling in liver cancer. Exp Opin Ther Targets. 2012; 16:243-247.
38. Liu AM, Xu MZ, Chen J, Poon RT, Luk JM. Targeting YAP and hippo signaling pathway in liver cancer. Exp Opin Ther Targets. 2010; 14:855-868.
39. Johnson R, Halder G. The two faces of hippo: targeting the hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014; 13:63-79.
40. Hydbring P, Badalian-Very G. Clinical applications of microRNAs. F1000Research. 2013; 2:136.